Frontal Intermittent Rhythmic Delta Activity Is a Useful Diagnostic Tool of Neurotoxicity After CAR T-Cell Infusion
暂无分享,去创建一个
N. Menjot de Champfleur | P. Labauge | X. Ayrignac | G. Cartron | C. Duflos | S. Badiou | P. Gélisse | G. Taieb | J. Tudesq | S. Lamure | L. Platon | Sophie Huby | Marc-Antoine Gallerand
[1] A. Stracciari,et al. Frontal predominant encephalopathy with early paligraphia as a distinctive signature of CAR T-cell therapy-related neurotoxicity , 2021, Journal of Neurology.
[2] C. Jacobson,et al. EEG findings in CART T associated neurotoxicity: clinical and radiological correlations. , 2021, Neuro-oncology.
[3] Matthew J. Frigault,et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events , 2020, Journal for ImmunoTherapy of Cancer.
[4] É. Azoulay,et al. Description of neurotoxicity in a series of patients treated with CAR T-cell therapy , 2020, Scientific Reports.
[5] S. Nikiforow,et al. Clinical Predictors of Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy. , 2020, JAMA neurology.
[6] Matthew J. Frigault,et al. Language dysfunction-associated EEG findings in patients with CAR-T related neurotoxicity , 2020, BMJ Neurology Open.
[7] Keuntae Kim,et al. Clinical Correlates of Frontal Intermittent Rhythmic Delta Activity Without Structural Brain Lesion , 2020, Clinical EEG and neuroscience.
[8] Xiuhua Bozarth,et al. EEG Correlates of Delirium in Children and Young Adults With CD19-Directed CAR T Cell Treatment-Related Neurotoxicity. , 2019, Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society.
[9] Matthew J. Frigault,et al. Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. , 2019, Blood.
[10] M. Christ-Crain,et al. Copeptin and its role in the diagnosis of diabetes insipidus and the syndrome of inappropriate antidiuresis , 2019, Clinical endocrinology.
[11] C. Jacobson,et al. Neurological toxicities associated with chimeric antigen receptor T-cell therapy. , 2019, Brain : a journal of neurology.
[12] S. Grupp,et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[13] G. Salles,et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B‐Cell Lymphoma , 2019, The New England journal of medicine.
[14] M. Westover,et al. EEG findings in CAR T-cell therapy-related encephalopathy , 2018, Neurology.
[15] L. Deangelis,et al. Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia. , 2018, Cancer discovery.
[16] K. Davis,et al. Tisagenlecleucel in Children and Young Adults with B‐Cell Lymphoblastic Leukemia , 2018, The New England journal of medicine.
[17] R. Levy,et al. Axicabtagene Ciloleucel CAR T‐Cell Therapy in Refractory Large B‐Cell Lymphoma , 2017, The New England journal of medicine.
[18] R. Kakigi,et al. Electroencephalographic Dipole Source Modeling of Frontal Intermittent Rhythmic Delta Activity , 2012, Neuropsychobiology.
[19] R. Zietse,et al. Hyponatremia and Inflammation: The Emerging Role of Interleukin-6 in Osmoregulation , 2010, Nephron Physiology.
[20] Michael J Brammer,et al. Functional magnetic resonance imaging of verbal fluency and confrontation naming using compressed image acquisition to permit overt responses , 2003, Human brain mapping.
[21] V. Synek,et al. Prognostically Important EEG Coma Patterns in Diffuse Anoxic and Traumatic Encephalopathies in Adults , 1988, Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society.